Leading a high-performing team and driving international market breast cancer strategy to enhance overall performance. Collaborating closely with top 10 markets to execute strategies and spearheading efforts to boost cross functional cooperation for improved patient impact and market leadership.

Focused on key Solid Tumor Therapeutic area strategies and initiatives. Working and supporting Global, IMI team to develop and execute world class future looking US First strategies for Breast, Prostate, Lung & GI

Lung WDSL, a core member of the Global Program Team (GPT), and point person for providing commercial input across all current and future indications and new products within Lung. Highly strategic role contributes to the development and execution of the Disease Area Strategy (DAS) and life cycle management plans for all assets within lung including business cases development , ROI assessments and BD&L opportunities. Provide strategic leadership with cross-functional GPT members to ensure cohesion and brand integrity, pricing, safety, messaging, pharmacovigilance , regulatory interactions, manufacturing, packaging, distribution, and supply forecasting across indications , current indications, current portfolio, and future pipeline across different platforms within Lung disease area.

Melanoma GDSL, a core member of the Global Program Team (GPT), and the point person for providing commercial input across all current and future indications and new products within Melanoma. Collaborating with global , regional, and country colleagues ensuring representation of all commercial interests to GPT. Reporting to the Melanoma Global Disease Lead (GDL) and working with Global Program Head (GPH) and broader GPT members , the GDSL is a senior commercial role focused exclusively on success of the entire portfolio management within Melanoma

Global Launch lead for BYL719(Alpelisib) , leading global x-functional teams to develop launch excellence strategy in collaboration with top markets and regions. Responsible of IDAPs strategic process and partnering with Medical affairs and Market access to develop BC indication strategy and tactics. Ensure launch readiness and excellence in wave 1 countries for best in class launch.

General Manager role with full P&L responsibility for clinical and commercial development of cancer medicines in GCC countries ( ex KSA). Direct reports include Business Franchise Heads , Head of Medical , Head of Market Access and Head of Finance. HR Business partner as part of Gulf unit Leadership team.

Business Franchise Head responsible for commercial development of Hematology cancer medicines leading sales and marketing teams in GCC countries ( ex, KSA). Direct reports include Sales and Brand managers.

Leading commercialisation of oncology medicines in GCC countries with sales and marketing responsibility. Direct reports include product specialists.

Responsible for marketing strategies and plans implementation and execution for oncology medicines in GCC countries.